BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• 

  Ronald A. Li

  Ronald A. Li, PhD, is CEO and co-founder of Medera.
• 

  Roger Hajjar

  Roger Hajjar, MD, is CMO and co-founder of Medera.
  
• 

  Rare diseases

  Harmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo Response

  While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.

  September 25, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  FDA

  FDA Details Thinking for Streamlining Development of Cell, Gene, Regenerative Therapies

  Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the development of cell and gene therapies.

  September 25, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Lilly Cuts Mid-Stage Obesity Study of Muscle-Sparing Antibody

  The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials database.

  September 25, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  $100,000 H-1B Fee Leaves Biopharma Grappling With Impact

  The Trump administration’s recently announced fee for new H-1B visa petitions is “completely unreasonable,” an immigration attorney told BioSpace. Attorneys and talent acquisition experts discuss how the fee could impact biopharma and confusion around the proclamation.

  September 25, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Job Trends

  6 Companies Hiring Now in Pennsylvania

  Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.

  September 25, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Pancreatic cancer

  Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months

  Truist analysts called the results “encouraging” while pointing out certain unknowns in the data. Immuneering plans to kick off a registrational trial for atebimetinib later this year.

  September 25, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  FDA Approves Crinetics’ Once-Daily Acromegaly Treatment

  The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with the rare pituitary condition. It’s the first approval for Crinetics Pharmaceuticals and something CEO Scott Struthers predicted “will transform people’s lives.”

  September 25, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• Press Releases

  PepGen Announces Proposed Public Offering

  September 25, 2025

   · 

  3 min read